Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/1Yao.com, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.

Private Company Edition: The Alliance for Regenerative Medicine’s half-year report shows the sector raised $10.7bn in the first half of 2020 versus $9.8bn raised in all of 2019. Also, DCVC Bio closed a $350m fund, new incubator opportunities and VC mega-deals for Dyne and Atomwise.

Partnership will combine AbCellera’s screening of antibodies to the virus with Lilly’s development, commercial capabilities. Vir adds Biogen tie-up to its ongoing coronavirus efforts.

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.